Human Menstrual Blood-Derived Stem Cells Protect against Tacrolimus-Induced Islet Dysfunction via Cystathionine β-Synthase Mediated IL-6/STAT3 Inactivation
Biomolecules · 2024
DOI: 10.3390/biom14060671 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2024. Verfasst von Jiamin Fu und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical …. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Tacrolimus, Interleukin-6, Cystathionine beta-Synthase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, Fundamental Research Funds for the Central Universities, Zhejiang Key Research and Development Program.
Abstract (Originalsprache)
Diabetes imposes a huge burden worldwide. Islet transplantation is an alternative therapy for diabetes. However, tacrolimus, a kind of immunosuppressant after organ transplantation, is closely related to post-transplant diabetes mellitus. Mesenchymal stem cells (MSCs) have attracted interest for their potential to alleviate diabetes. In vivo experiments revealed that human menstrual blood-derived stem cells (MenSCs) treatment improved tacrolimus-induced blood glucose, body weight, and glucose tolerance disorders in mice. RNA sequencing was used to analyze the potential therapeutic targets of MenSCs. In this study, we illustrated that cystathionine β-synthase (CBS) contributed to tacrolimus -induced islet dysfunction. Using β-cell lines (MIN6, β-TC-6), we demonstrated that MenSCs ameliorated tacrolimus-induced islet dysfunction in vitro. Moreover, MenSC reduced the tacrolimus-induced elevation of CBS levels and significantly enhanced the viability, anti-apoptotic ability, glucose-stimulated insulin secretion (GSIS), and glycolytic flux of β-cells. We further revealed that MenSCs exerted their therapeutic effects by inhibiting CBS expression to activate the IL6/JAK2/STAT3 pathway. In conclusion, we showed that MenSCs may be a potential strategy to improve tacrolimus-induced islet dysfunction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Di…
- Research Units of Infectious Disease and Microecology, Chinese Academy of Medical Sciences, Hangzhou 310003, China.
- Innovative Precision Medicine (IPM) Group, Hangzhou 311215, China.
- Jinan Microecological Biomedicine Shandong Laboratory, Jinan 250117, China.
ORCID-Profile: Jiamin Fu, Lijun Chen
Förderung
- National Key R&D Program of China
- Fundamental Research Funds for the Central Universities
- Zhejiang Key Research and Development Program
- Shandong Provincial Laboratory Project
- National Key R&D Program of China
Zitieren
APA
Fu, J., Zhang, Q., Zhang, N., Zhou, S., Fang, Y., Li, Y., Yuan, L., Chen, L., & Xiang, C. (2024). Human Menstrual Blood-Derived Stem Cells Protect against Tacrolimus-Induced Islet Dysfunction via Cystathionine β-Synthase Mediated IL-6/STAT3 Inactivation. Biomolecules. https://doi.org/10.3390/biom14060671
Vancouver
Fu J, Zhang Q, Zhang N, Zhou S, Fang Y, Li Y, et al. Human Menstrual Blood-Derived Stem Cells Protect against Tacrolimus-Induced Islet Dysfunction via Cystathionine β-Synthase Mediated IL-6/STAT3 Inactivation. Biomolecules. 2024. doi:10.3390/biom14060671
BibTeX
@article{Fu2024,
author = {Fu, Jiamin and Zhang, Qi and Zhang, Ning and Zhou, Sining and Fang, Yangxin and Li, Yifei and Yuan, Li and Chen, Lijun and Xiang, Charlie},
title = {Human Menstrual Blood-Derived Stem Cells Protect against Tacrolimus-Induced Islet Dysfunction via Cystathionine β-Synthase Mediated IL-6/STAT3 Inactivation},
journal = {Biomolecules},
year = {2024},
doi = {10.3390/biom14060671}
}
EUVIMED